Good Health Medicine

Main Menu

  • Home
  • Health medicine
  • Dietary supplements
  • Dietary nutrition
  • Alternative medication
  • Medicine price

Good Health Medicine

Header Banner

Good Health Medicine

  • Home
  • Health medicine
  • Dietary supplements
  • Dietary nutrition
  • Alternative medication
  • Medicine price
Health medicine
Home›Health medicine›FDA panel skeptical of controversial ALS drug ahead of vote | Health, Medicine and Fitness

FDA panel skeptical of controversial ALS drug ahead of vote | Health, Medicine and Fitness

By Rebecca C. Myers
September 6, 2022
0
0

Cara Murez

TUESDAY, Sept. 6, 2022 (HealthDay News) — A U.S. Food and Drug Administration panel will again consider approval of an investigational drug for ALSa rare second review for a disease that has no cure.

The same panel that will meet on Wednesday vote last March not to approve the drug for the fatal neurodegenerative disease also known as Lou Gehrig’s disease.

But getting the drug, known as Albrioza (AMX0035), approved is a rallying cause for patients, their families and members of Congress, the Associated Press reported.

People also read…

Yet federal regulators said in a information document filed Friday that the company’s new evidence was not “sufficiently independent or compelling” to establish efficacy.

The paper said experts could consider “unmet need in ALS” and the flexibility the agency has to seek approval for drugs that treat life-threatening conditions.

This suggests “there is a chance the FDA is still looking for a way to approve the product,” SVB analyst Marc Goodman wrote in a note to investors. Goodman thinks the drug has about a 50% chance of being approved, the PA reported.

When regulators first reviewed the drug in March, they voted against it 6 to 4 after finding the data was not convincing that it would benefit people with the disease. The panel gave the agency until September 29 to review any further data submitted by the company.

Canadian regulators have already approved the drug for ALS patients, which puts the FDA in a “precarious position,” bioethicist Holly Fernandez-Lynch told the PA.

“They generally like to be ahead when making approval decisions,” said Fernandez-Lynch, who teaches at the University of Pennsylvania. “They like to argue that they’re not a barrier to patients getting things that might help them.”

Amylyx Pharmaceuticals, which makes the drug, said it collected follow-up data on the study which concluded the drug extended the lives of ALS patients by about 10 months.

The drug combines a dietary supplement used in traditional Chinese medicine with an existing prescription medication for liver disorders. The combination protects the cells from premature death, according to Amylyx.

Approval of the combination drug could force insurers to cover it.

But the trial had missing data and implementation errors, according to FDA reviewers. It “still suffers from the same interpretability issues,” they wrote.

ALS patients eventually stop walking, talking, swallowing, and breathing, and typically die within three to five years of diagnosis, as the disease methodically destroys nerve cells.

External contributions will come from patient groups and advocacy groups, including I AM ALS, founded by patient Brian Wallach. Wallach takes the food supplement for the treatment.

“Patients are doing their homework – we know this isn’t going to cure us,” said Wallach, who was diagnosed with ALS in 2017 and spoke through an interpreter. PA. “But we also know it could keep us here until the next drug comes and that could be a cure.”

The US National Institute of Neurological Disorders and Stroke has more on ALS.

SOURCE: US Food and Drug Administration, Briefing Paper, September 2, 2022; Associated Press

Related posts:

  1. Living with a Short Sleep Gene: “It’s a Gift” | Health, medicine and fitness
  2. COVID counts remain low in Nebraska; vaccination figures fall | Health, medicine and fitness
  3. The Best Over-The-Counter Allergy Relief Options Health, medicine and fitness
  4. FACTS FOR FAMILIES: Where to get your vitamin D | Health, medicine and fitness
  • Alternative medication
  • Dietary nutrition
  • Dietary supplements
  • Health medicine
  • Medicine price
  • Survey compares how consumers and nutrition experts rate healthy foods – AgriNews
  • Bone & Joint Health Supplements Market to Witness a CAGR of 8% (2022-2028) Driven by Growing Prevalence of Orthopedic Disorders and Micronutrient Deficiencies | UnivDatos Market Overview
  • Police arrest scammer entangling hundreds of IPB students in online loans
  • Know which one is better for nutrition, skin and health
  • Your answers on cancer: What to know about stomach cancer? | Health, Medicine and Fitness
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • August 2020
  • May 2020
  • March 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • March 2018
  • February 2018
  • January 2018
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • August 2016
  • June 2016
  • May 2016
  • February 2016
  • October 2015
  • August 2015
  • April 2015
  • March 2014
  • December 2013
  • September 2012
  • October 2011
  • September 2011
  • July 2011
  • June 2011
  • April 2011
  • March 2011
  • March 2010
  • September 2007
  • Privacy Policy
  • Terms and Conditions